**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 76807

**Manuscript Type:** LETTER TO THE EDITOR

**Colitis and colorectal tumors should be further explored and differentiated**

Xu D *et al*. Colitis and colorectal tumors

Dong-Hui Xu, Bo Zhou, Zhi-Peng Li, Lian-Ping He, Xin-Juan Wang

**Dong-Hui Xu, Bo Zhou, Zhi-Peng Li, Lian-Ping He, Xin-Juan Wang,** School of Medicine, Taizhou University, Jiaojiang 318000, Zhejiang Province, China

**Author contributions:** Wang XJ and He LP conceived of the presented idea and provided critical feedback to the final manuscript, revised the manuscript and approved the main conceptual ideas and outline; Xu DH, Zhou B, and Li ZP wrote the manuscript; all authors provided final edits and approved the manuscript.

**Supported by** the General Research Project of Education Department of Zhejiang Province, No. Y202146955; and the Second Batch of Research Projects on Teaching Reform in the 13th Five-year Plan of Zhejiang Province, No. Jg20190460.

**Corresponding author: Xin-Juan Wang, MD, Senior Researcher,** School of Medicine, Taizhou University, No. 1139 Shifu Avenue, Jiaojiang District, Taizhou 318000, Zhejiang Province, China. wxjyxy@tzc.edu.cn

**Received:** April 1, 2022

**Revised:** May 1, 2022

**Accepted: July 16, 2022**

**Published online:**

**Abstract**

The original article by Yuichi *et al* explored whether the Japan Narrow-Band Imaging Expert Team classification and the pit pattern classification are suitable for diagnosing neoplastic lesions in patients with ulcerative colitis. In this letter, we offer some other perspectives. Risk factors for colorectal tumors include type 2 diabetes. Among genetic factors, the deletion or mutation of some genes, such as the p53 gene, can lead to colorectal tumors. There are significant gender differences in the occurrence and development of colorectal tumors. Some non-genetic factors, such as smoking, are also associated with the development of colorectal tumors. These all suggest that colorectal tumors are not only caused by ulcerative colitis, and we suggest further exploration and differentiation between colitis and colorectal tumors.

**Key Words:** Colorectal cancer; Nicotine; p53; Tobacco; Ulcerative colitis

Xu DH, Zhou B, Li ZP, He LP, Wang XJ. Colitis and colorectal tumors should be further explored and differentiated. *World J Gastrointest Oncol* 2022; In press

**Core Tip:** Among genetic factors, the deletion or mutation of some tumor suppressor genes can lead to colorectal tumors. Non-genetic factors are also associated with the development of colorectal tumors. The underlying disease can be a risk factor for colorectal tumors. There are significant gender differences in the occurrence and development of colorectal tumors. These all suggest that colorectal tumors are not only caused by ulcerative colitis, and we suggest further exploration and differentiation between colitis and colorectal tumors.

**TO THE EDITOR**

We read with great interest the study by Kida Y *et al*[1] which was published in the world journal of gastroenterology. The study focused on whether the Japan Narrow-Band Imaging Expert Team (JNET) classification and pit pattern classification are applicable for diagnosing neoplastic lesions in patients with ulcerative colitis (UC). This study found that The JNET and pit pattern classifications did not show high accuracy in diagnosing the pathology and invasion depth of neoplastic lesions in UC patients. Endoscopic diagnosis of neoplastic lesions in UC patients is still difficult and treatment strategies need to be carefully determined. Although the authors' findings provide new methods and ideas for existing diagnosis and treatment problems, our team agrees that there are still some issues that need further discussion in this paper.

In the case of genetic factors, environmental factors, living habits, and other adverse factors, everyone is theoretically at risk of developing colorectal tumors. The study by Simon[2] showed that genetic disorders such as Lynch syndrome, a personal history of inflammatory bowel disease, and type 2 diabetes are all predisposing factors for developing colorectal tumors. In genetic factors, deletion or mutation of some genes, such as the p53 gene, can also lead to colorectal tumors[3,4]. There are significant gender differences in the development of colorectal tumors, and the colorectum is a common tumor-producing organ in both men and women[5]. The study by Kim *et al*[6] showed that women over 65 had higher colorectal cancer mortality compared with men of the same age group. Colorectal cancer detection time and mortality are related to the site of colorectal cancer. Compared with right-sided colon cancer, left-sided colon cancer was detected later and more differentiated. In clinical work, it was found that the proportion of right-sided colorectal cancer in women is much higher than in men. All of the above evidence suggests that the mortality rate of female patients with colorectal cancer may be higher than that of male patients.

Some non-genetic factors, such as smoking, are also associated with the development of colorectal tumors. Among the etiologies of non-hereditary colorectal tumors, smoking has local and systemic effects on the colorectal mucosa through the production of carcinogens[7]. The nicotine in tobacco is potentially addictive and increases the patient’s dependence on tobacco, thereby increasing the risk of colorectal cancer. In addition, the mutation rate of tumor suppressor genes in smokers was significantly higher than in non-smokers. Among the many mutant genes, the p53 gene mutation is the most important. These phenomena are related to the occurrence and development of colorectal tumors. The study by Siegel *et al*[8] shows that women under 49 are about 3% more likely to die than men.

In summary, colorectal tumors are not only caused by ulcerative colitis. Research by Curtin K shows that smoking (> 20 pack-years *vs* non-smokers) was associated with TP53 mutations (OR = 1.4, 95%CI 1.02-2.0), BRAF mutations (OR = 4.2, 95%CI 1.3-14.2), and MSI mutations (OR = 1.4, 95%CI 1.02-2.0) in rectal tumors and was associated with an increased risk of rectal cancer. Long-term exposure to > 10 h/wk of environmental tobacco smoke was associated with an increased risk of KRAS2 mutations (OR = 1.5, 95%CI 1.04-2.2)[9]. Colorectal cancer is also related to genetic factors, living habits, eating habits, *etc.* It may not be clear that patients with chronic ulcerative colitis developed colorectal tumors due to chronic inflammation in this study. To further explore whether chronic ulcerative colitis is a risk factor for colorectal tumors, genetic factors, dietary habits, lifestyle habits and other factors need to be further discussed.

Type 2 diabetes has been shown to be a risk factor for colorectal tumors. Among genetic factors, deletion or mutation of some genes, such as the p53 gene, can lead to colorectal tumors. There are significant gender differences in the occurrence and development of colorectal tumors. Some non-genetic factors, such as smoking, are also associated with the development of colorectal tumors. These all suggest that colorectal tumors are not only caused by ulcerative colitis. Therefore, we suggest further exploration and differentiation between colitis and colorectal tumors.

**REFERENCES**

1 **Kida Y**, Yamamura T, Maeda K, Sawada T, Ishikawa E, Mizutani Y, Kakushima N, Furukawa K, Ishikawa T, Ohno E, Kawashima H, Nakamura M, Ishigami M, Fujishiro M. Diagnostic performance of endoscopic classifications for neoplastic lesions in patients with ulcerative colitis: A retrospective case-control study. *World J Gastroenterol* 2022; **28**: 1055-1066 [PMID: 35431498 DOI: 10.3748/wjg.v28.i10.1055]

2 **Simon K**. Colorectal cancer development and advances in screening. *Clin Interv Aging* 2016; **11**: 967-976 [PMID: 27486317 DOI: 10.2147/CIA.S109285]

3 **Kadosh E**, Snir-Alkalay I, Venkatachalam A, May S, Lasry A, Elyada E, Zinger A, Shaham M, Vaalani G, Mernberger M, Stiewe T, Pikarsky E, Oren M, Ben-Neriah Y. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. *Nature* 2020; **586**: 133-138 [PMID: 32728212 DOI: 10.1038/s41586-020-2541-0]

4 **Cho YH**, Ro EJ, Yoon JS, Mizutani T, Kang DW, Park JC, Il Kim T, Clevers H, Choi KY. 5-FU promotes stemness of colorectal cancer *via* p53-mediated WNT/β-catenin pathway activation. *Nat Commun* 2020; **11**: 5321 [PMID: 33087710 DOI: 10.1038/s41467-020-19173-2]

5 **Hendifar A**, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ. Gender disparities in metastatic colorectal cancer survival. *Clin Cancer Res* 2009; **15**: 6391-6397 [PMID: 19789331 DOI: 10.1158/1078-0432.CCR-09-0877]

6 **Kim SE**, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities in colorectal cancer risk. *World J Gastroenterol* 2015; **21**: 5167-5175 [PMID: 25954090 DOI: 10.3748/wjg.v21.i17.5167]

7 **Cappellani A**, Zanghì A, Di Vita M, Cavallaro A, Piccolo G, Veroux P, Lo Menzo E, Cavallaro V, de Paoli P, Veroux M, Berretta M. Strong correlation between diet and development of colorectal cancer. *Front Biosci (Landmark Ed)* 2013; **18**: 190-198 [PMID: 23276917 DOI: 10.2741/4095]

8 **Siegel RL**, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. *CA Cancer J Clin* 2017; **67**: 177-193 [PMID: 28248415 DOI: 10.3322/caac.21395]

9 **Curtin K**, Samowitz WS, Wolff RK, Herrick J, Caan BJ, Slattery ML. Somatic alterations, metabolizing genes and smoking in rectal cancer. *Int J Cancer* 2009; **125**: 158-164 [PMID: 19358278 DOI: 10.1002/ijc.24338]

**Footnotes**

**Conflict-of-interest statement:** All authors declare no potential conﬂicts of interest with respect to the research, authorship, and/or publication of this article. All other authors have read the manuscript and have agreed to submit it in its current form for consideration for publication in the world Journal of Gastrointestinal Oncology.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 1, 2022

**First decision:** May 1, 2022

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Lin JC, Taiwan; Ogino S, United States; Sica G, Italy **S-Editor:** Wang LL **L-Editor:** Filipodia **P-Editor:** Wang LL